Why an abortion pill fallback isn't ideal; generics makers may end up benefiting from new drug pricing law

This month, a federal court judge could rule on whether to overrule the FDA's approval of the abortion drug mifepristone in 2000.

February 10, 2023 Check out STAT+

Sponsored By

ROBYN BECK/AFP via Getty Images As ban on one abortion pill looms, providers look to the other as a fallback. But that isn't ideal This month, a federal court judge could rule on whether to overrule the FDA's approval of the abortion drug mifepristone in 2000. By Eric Boodman STAT+ | Generics companies fought to stop the new drug pricing law. But they may end up benefiting Generic drugmakers lobbied hard against letting Medicare negotiate drug prices. But they may end up benefiting from it. By John Wilkerson STAT+ | A CAR-T from Bristol Myers benefits myeloma patients at earlier stage of care The CAR-T cancer therapy called Abecma reduced the risk of multiple myeloma relapse by half compared to standard treatment. By Adam Feuerstein Adobe Opinion: Pregnancy complications heighten heart risks in later life. It's time to pay attention Pregnancy-related problems like preeclampsia are on the rise. That could herald an increase in heart disease down the road. By Nisha Parikh and Alison Cowan STAT+ | What a hospital oligopoly looks like A financial filing from a large, tax-exempt Orlando hospital provides a glimpse of just how concentrated America's hospital markets are. By Bob Herman Opinion: CVS's acquisition of Oak Street doesn't address health care's woes Acquisitions of primary care companies do little to improve U.S. health care. What's needed is more direct primary care. By Zak Holdsworth Adobe Opinion: To diversify STEM fields, colleges should replace 'weeding out' with 'welcoming in' STEM fields need more women and individuals from underrepresented groups. There are several ways to welcome them in and help them flourish. By Paula A. Johnson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser